TAPinto.netImmunotherapy Clinical Trial at Overlook Medical Center Reveals Brain Tumor Shrinkage, Continues with Phase 3 StudyTAPinto.netSUMMIT, NJ – Following successful Phase 1 clinical trials, the Toca regimen – a new immunotherapy for patients with… Continue reading
Motley Fool |
Could Celgene Shake Up the CAR–T Market?
Motley Fool The current CAR-T party of two might have a couple of new companions on the way. And those new entrants could bring some excitement to the party. Only two chimeric antigen T–cell receptor (CAR-T) therapies are currently approved by the FDA — Novartis’ … Celgene Presents Data on CAR T Therapy, Revlimid & PomalystNasdaq bluebird shares recover after slump following ASCO CAR–T data presentationMedCity News Celgene (CELG), bluebird bio (BLUE) Phase I Study of bb2121 Demonstrates Deep and Durable Responses at ASCOStreetInsider.com |
R & D Magazine |
ASCO 2018: More Lung Cancer Patients Could Benefit From Immunotherapy Over Chemo
R & D Magazine A new study demonstrates that immunotherapeutic agent pembrolizumab (Keytruda) is more effective than chemotherapy as a first-line treatment for most patients with a common type of lung cancer, regardless of patients’ expression of PD-L1, a protein … |